Tevogen Bio (TVGN) Highlights Promising Trial Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. AVGO
2. CDNS
3. SPY
4. META
5. ANT
6. SSD
7. AAPL
8. JBLU
9. PECO
10. ARTV

Go back to Tevogen Bio (TVGN) Highlights Promising Trial Data

Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Med

October 8, 2024 2:40 PM EDT

The primary study endpoints were related to safety. No dose-limiting toxicities or significant adverse events related to TVGN 489, including Cytokine Release Syndrome, were observed in any patient at any dose level.  Endpoints measuring the reduction of viral load and the presence of cellular and humoral anti-COVID-19 responses after treatment were met. Fifty percent (50%) of treatment arm patients were immunocompromised versus six percent (6%) of observational arm patients. Treatment arm patients were infected by a variety of SARS-CoV-2 variants ranging from Delta through Omicron... More